首页> 美国卫生研究院文献>other >Relaxivity and toxicological properties of manganese oxide nanoparticles for MRI applications
【2h】

Relaxivity and toxicological properties of manganese oxide nanoparticles for MRI applications

机译:用于MRI应用的氧化锰纳米颗粒的弛豫性和毒理学性质

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Manganese oxide nanoparticles (MONs) have received growing attention as alternative T1 MRI contrast agents due to the association of commercial gadolinium-based contrast agents with nephrogenic systemic fibrosis. Since the seminal publication first describing the use of MONs as positive T1 contrast agents, there is an ongoing impetus to develop MONs of higher T1 signal intensity for better diagnostic efficacy. Indeed, various MON-based nanoprobe designs have been proposed, such as the employment of a mesoporous nanomaterial with MONs evenly dispersed within, or the traditional coating of a biocompatible layer onto the surface of MONs to form a core–shell configuration. Recent advances in this field also propose stimuli-responsive MONs that capitalize on an acidic dissolution or in situ reduction to release Mn2+ ions for a multi-fold increase in MRI contrast. However, the potential nanotoxicity of MONs remains a key obstacle to the clinical translation of MON-based T1 contrast agents. Due to the wide variety of functionalities and physicochemical properties of MONs, there is also a lack of consensus on the toxicological properties of MONs. In addition, the r1 relaxivity of MRI contrast agents typically decreases at higher field strength. Hence, it highlights the need to develop MON-based contrast agents with higher relaxivities. In this regard, this article aims to present a thorough review of MONs for MRI applications, with particular emphasis on their relaxivity and toxicological properties. In order to systematically review the current state-of-the-art for the development of MONs for MRI applications, the MON-based T1 contrast agents are categorized based on the structure of the nanomaterial system. Key parameters that influence the nanotoxicity of MONs are also examined while the absorption, distribution, metabolism and excretion of MON in vivo are evaluated to discern how long the nanoparticles will be present within the body, as well as to predict the organs or tissues in which they distribute.
机译:由于商业上基于contrast的造影剂与肾原性系统性纤维化的关系,氧化锰纳米颗粒(MONs)作为替代性T1 MRI造影剂受到了越来越多的关注。自从开创性出版物首次描述了将MONs用作阳性T1造影剂以来,就一直在推动开发更高T1信号强度的MONs以获得更好的诊断功效。确实,已经提出了各种基于MON的纳米探针设计,例如采用MONs均匀分散在其中的中孔纳米材料,或在MONs表面上形成传统的生物相容性涂层以形成核-壳结构。该领域的最新进展还提出了刺激响应的MONs,该MONs利用酸性溶解或原位还原来释放Mn 2 + 离子,从而使MRI对比度增加了几倍。但是,MONs的潜在纳米毒性仍然是基于MON的T1造影剂临床翻译的主要障碍。由于MONs的功能和理化特性多种多样,因此在MONs的毒理学特性上也缺乏共识。此外,MRI造影剂的r1弛豫度通常在较高的场强下会降低。因此,它强调了开发具有更高弛豫度的基于MON的造影剂的需要。在这方面,本文旨在对MRI应用的MONs进行全面的回顾,特别强调其弛豫性和毒理学特性。为了系统地回顾用于MRI应用的MONs开发的最新技术,基于纳米材料系统的结构对基于MON的T1造影剂进行了分类。还检查了影响MONs纳米毒性的关键参数,同时评估了MON在体内的吸收,分布,代谢和排泄,以识别纳米粒子在体内的存在时间,并预测其中的器官或组织。他们分发。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号